Diabetes Dr. J. Antony Gagnon, Pharm.D., CDE, CAE

Slides:



Advertisements
Similar presentations
University of Georgia Cooperative Extension. Why Change Eating Habits? To prevent complications of diabetesTo prevent complications of diabetes –by keeping.
Advertisements

DO YOU HAVE THE METABOLIC SYNDROME? You're never too young to have it Jacqueline A. Eberstein, R.N.
Diabetes Mellitus in Clinical Practice Dr. Muhieddin Omar Dr. Raed Abu Sham’a.
BLOOD PRESSURE LOWERING. UKPDS design Aim To determine whether intensified blood glucose control, with either sulphonylurea or insulin, reduces the risk.
CVD risk estimation and prevention: An overview of SIGN 97.
Glucose Tolerance Test Diabetes Mellitus Dr. David Gee FCSN Nutrition Assessment Laboratory.
Diabetes in Pregnancy Screening.
Canadian Diabetes Association Clinical Practice Guidelines Dyslipidemia Chapter 24 G. B. John Mancini, Robert A. Hegele, Lawrence A. Leiter.
Benefits of intensive multiple risk factor intervention.
Lipids 101 Cardiology Board Review Med-Peds Style!
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
Hypertension Diagnosis and Treatment  Based on JNC 7 – published in 2003  Goal: BP
ADVICE. Advice Strongly advise adherence to diet and medication Smoking cessation, exercise, weight reduction Ensure diabetes education and advise Diabetes.
Dyslipidemia/Lipid management in Diabetes. M ECHANISMS R ELATING I NSULIN R ESISTANCE AND D YSLIPIDEMIA  TG  Apo B  VLDL (hepatic lipase) Kidney (CETP)CEHDL.
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.
Linked Metabolic Abnormalities:
Canadian Diabetes Association Clinical Practice Guidelines Vascular Protection in People with Diabetes Chapter 22 James A. Stone, David Fitchett, Steven.
TM © 1999 Professional Postgraduate Services ® S: Total Mortality Reduction in a Subgroup of Patients With Diabetes Proportion.
DYSLIPIDEMIA IN ADULTS WITH DIABETES* 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada *Updated in Leiter.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
Stroke Awareness & Prevention Suheb Hasan, MD Health Seminar MCWS November 17, 2012.
Nutrition and Cardiovascular Disease. Cardiovascular Disease Includes heart attack, stroke Includes heart attack, stroke Leading cause of death in the.
METABOLIC Syndrome: a Global Perspective
1 Presenter Disclosure Information FINANCIAL DISCLOSURE: DSMB’s: Merck, Takeda Barry R. Davis, MD, PhD Clinical Outcomes in Participants with Dysmetabolic.
Criteria for Diagnosis of DM * Testing must be repeated on separate day. FPG is the preferred test ** Symptoms of DM IFG = Impaired fasting glucose IGT.
Diabetes Mellitus Ibrahim Sales, Pharm.D. Assistant Professor of Clinical Pharmacy King Saud University
Management of Chronic Stable Angina AIMGP Seminar Series Mirek Otremba 2007.
What the GP Should Know about Diabetes Mellitus Dr. Muhieddin Omar.
Metabolic Syndrome Yusra Mir, MD Zunairah Syed, MD Harjagjit Maan, MD.
1 Hypertension Overview. 2 Leading Risks For Death (World Health Organization 2002) Cholesterol Alcohol HYPERTENSION Tobacco use Overweight.
CARDIOVASCULAR CARE of the OUTPATIENT Diane M. Enzweiler, MSN, ANP-BC St. Elizabeth Physicians: Heart and Vascular.
STOPPING DIABETES STARTS NOW What is Diabetes? Diabetes Epidemic? Risk Factors? Complications of Diabetes? Preventing Diabetes Complications?
Screening for Type 1 & Type 2 Diabetes Key Messages In the absence of evidence for interventions to prevent or delay type 1 diabetes, screening for type.
Diabetes mellitus “ Basic approach” Dr Sajith.V.S MBBS,MD (Gen Med )
January 2013 Webinar: “Practical Ways to Help Get Our Diabetes Patients to Goal” Controlling the ABC’s Cases.
HYPERLIPIDEMIA Applied Therapeutics Dr. Riyadh Mustafa Al-Salih.
MACROVASCULAR COMPLICATIONS, DYSLIPIDEMIA and HYPERTENSION 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Diabetes Update Laurel Mullally C-FNP. Diabetes Incidence 20.8 million US children and adults have diabetes (1/3 undiagnosed) 20.8 million US children.
CVD &Dietary management. :Learning objectives Good To know the risk factors of CHD, HAVE to know: general principles of nutritional therapy, Guidelines.
Diabetes. Objectives: Diabetes Mellitus (DM) Discuss the prevalence of diabetes in the U.S. Contrast the main types of diabetes. Describe the classic.
Prescribing in cardiovascular disease By Jole Hannan Medicines Optimisation Pharmacist.
Metabolic Syndrome Endocrine Block 1 Lecture Dr. Usman Ghani.
Prevention of diabetes complications The alphabet strategy.
Cardiometabolic Risk, Type 2 Diabetes and Cardiovascular Disease.
Yusra Mir, MD Zunairah Syed, MD Harjagjit Maan, MD
Blood Pressure and Lipid Trials: Rationale, Importance and Design
Copyright © 2015 by the American Osteopathic Association.
Endocrine Block 1 Lecture Dr. Usman Ghani
Screening for Diabetes in Pregnancy
Endocrine Block Dr. Usman Ghani
Managing Type 2 Diabetes
Managing Type 2 Diabetes
Endocrine Block 1 Lecture Dr. Usman Ghani
Life after a Cardiovascular Event
The Anglo Scandinavian Cardiac Outcomes Trial
Cardiovascular System
Diabetes Health Status Report
Heart Health & Diabetes
Chapter 10 Diet and Health
Screening for Diabetes in Pregnancy
Section I: RAS manipulation C. Update on clinical trials in CAD
Developing a Heart-Healthy Life Style
RCHC’s Cardiovascular Health Initiative
Non-communicable diseases (NCDs) II CVDs & DM
Goals & Guidelines A summary of international guidelines for CHD
Pandemic Lipid Edition
Dyslipidemia And Diabetes
Prepared by :Dr. Latifa Mari’e
ATP III Guidelines Drug Therapy FUTURE RESEARCH.
Presentation transcript:

Diabetes Dr. J. Antony Gagnon, Pharm.D., CDE, CAE Pharmacy Program Coordinator Hamilton Family Health Team

Pathophysiology of type 2 DM

Definitions FPG 2h PG Normal < 6.1 and < 7.8 IFG (isolated) 6.1 – 6.9 IGT (isolated) 7.8 – 11.0 IFG and IGT Diabetes > 7.0 and/or > 11.1 IFG: Impaired Fasting Glucose IGT: Impaired Glucose Tolerance 2h PG: 2-hour plasma glucose

Risk factors for diabetes 1st degree relative with diabetes High-risk population (e.g., Aboriginal) Hx of IGT or IFG Vascular disease Hypertension Dyslipidemia Overweight Abdominal obesity Schizophrenia Polycystic ovarian syndrome

Recommended targets for glycemic control A1C FPG or preprandial PG (mMol/L) 2-hour postprandial PG (mMol/L) Target for most patients < 0.07 4.0 – 7.0 5.0 – 10.0 Normal range (consider for patients in whom it can be achieved safely) < 0.06 4.0 – 6.0 5.0 – 8.0

Chronic complications of diabetes in relation to glucose control

Causes of death in patients with DM in Ontario

Risk of cardiovascular death

Vascular protection ACE inhibitor, as indicated Aspirin, as indicated BP control Glycemic control Lifestyle modifications Lipid control Smoking cessation

ACE inhibitors Micro-HOPE study (ramipril 10 mg daily) Total mortality - 24% CV death - 37% MI - 22% CVA - 33%

Aspirin (80 to 325 mg/d) Unless contraindicated, recommended in all patients with CVD or with atherosclerothic risk factors. If cannot tolerate aspirin can be substituted with Plavix (clopidogrel).

Blood pressure Risk reduction Diabetes-related death 24% Stroke 44% Microvascular disease 37% *Tight control (<14482 mmHg) vs less tight control (<154/87 mmHg)

Blood pressure targets SBP DBP DM < 130 <80 DM and proteinuria (> 1 g/d) < 125 < 75

Antihypertensive agents ACE inhibitors (ramipril, lisinopril, trandolapril, etc.) ARB (irbesartan, losartan, valsartan, telmisartan, etc.) Calcium Channel Blockers (amlodipine, felodipine,diltiazem, etc.) Beta-blockers (atenolol, metoprolol, etc.) Others

Cholesterol targets LDL (mMol/L) TC:HDL < 2.5 < 4.0

Lipid-lowering agents Statins (atorvastatin, rosuvastatin, simvastatin, pravastatin, fluvastatin) Fibrates (fenofibrate, gemfibrozil) Resins (cholestyramine, colestipol) Niacin

Nutrition

Nutrition Eat 3 meals / d at regular times and space meals no more than 6 h apart. Limits sugars and sweets such as sugar, regular pop, desserts, candies, jam, and honey. Limit amount of high fat food such as fried food, chips, and pastries. Increase amount of fibers (whole grain breads and cereals, fruits, and vegetables). If you are thirsty, drink water.

Physical activity Enhances insulin sensitivity and often weight loss Improves lipids (↓ TG, ↑ HDL) Improves blood pressure Enhances well-being ↓ risk of CVD 150 minutes per week, at least 10 min. at a time

Monitoring